1,268
Participants
Start Date
February 28, 2025
Primary Completion Date
December 1, 2026
Study Completion Date
December 1, 2026
PCV21
Investigational pneumococcal conjugate vaccine
20vPCV
20-valent pneumococcal conjugate vaccine
Site # 2330006, Tallinn
Site # 7640008, Bangkok
Site # 7640006, Bangkok
Site # 7640007, Bangkok
Site # 2330007, Tallinn
Site #8400010, Binghamton
Site # 8400025, Rochester
Site # 8400021, Fayetteville
Site # 8400004, Union City
Site # 8400014, Melbourne
Site # 8400007, Hialeah
Site # 8400024, Doral
Site # 8400009, Miami
Site # 8400016, Miami
Site # 8400018, Biloxi
Site # 8400012, Ridgeland
Site # 8400023, Erlanger
Site # 2330005, Tartu
Site # 7640003, Mueang Nonthaburi
Site # 7640004, Chiang Mai
Site # 2330004, Tartu
Site # 8400003, Sioux City
Site # 8400002, Omaha
Site # 2330001, Paide
Site # 8400017, Stephenville
Site # 8400001, Houston
Site # 7640002, Hat Yai
Site # 8400008, Paramount
Site # 2330002, Tallinn
Site # 2330003, Tallinn
Site # 6160009, Lodz
Site # 6160007, Warsaw
Site # 6160003, Częstochowa
Site # 6160002, Bydgoszcz
Site # 6160004, Bydgoszcz
Site # 6160006, Kłodzko
Site # 6160001, Torun
Site # 7640001, Pathum Thani
Sanofi Pasteur, a Sanofi Company
INDUSTRY